Navigation Links
Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
Date:4/4/2011

SAN FRANCISCO and ILLKIRCH, France, April 5, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) over the weekend at the Internationales Congress Centrum in Berlin, Germany.

The data from abstract #LB-283, entitled "JX-594, A Targeted Multi-Mechanistic Oncolytic Poxvirus, is Well-Tolerated and Exhibits Anti-Tumor Activity in Patients with Primary Liver Cancer and Liver Metastases," were presented by Caroline Breitbach, Ph.D., director of translational research.

"We are pleased to present these data on JX-594 at the EASL meeting, as they provide further evidence that both primary liver cancer and metastases to the liver can be treated safely with JX-594, with transient flu-like symptoms being the most common adverse events.  Anti-cancer activity continues to be clearly demonstrated in a broad spectrum of common solid tumor types," said David H. Kirn, M.D., president and chief executive officer of Jennerex.

"We look forward to reporting additional clinical results in patients with advanced liver cancer from two ongoing studies—a randomized Phase 2 trial of JX-594 evaluating survival across two dose groups, and a Phase 2 clinical trial evaluating JX-594 in combination with sorafenib," added Philippe Archinard, chairman and chief executive officer of Transgene.

Clinical Results

This presentation highlighted data from 35 patients with either primary liver cancer, known as hepatocellular carcinoma (HCC), or cancer metastases to the liver
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
2. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
3. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
4. Jennerex Appoints Lara Longpre to Chief Operating Officer
5. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
6. Jennerex Announces Presentations at Upcoming Conferences
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
9. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
10. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
11. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , 30. September 2014 ... http://photos.prnewswire.com/prnh/20130430/LA01948LOGO Acutus ... ein minimal-invasives 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in ... die zu komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern ... Abschluss einer zusätzlichen Finanzierung über 26,2 ...
(Date:9/30/2014)... , Sept. 30, 2014   Acutus ... minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole ... and / or sustain complex cardiac arrhythmias, including atrial ... to continue developing its imaging/mapping system as well as ... will allow Acutus Medical to complete work on the ...
(Date:9/30/2014)... 30, 2014 In 2011, approximately 5.1 million ... abused prescription pain relievers (e.g. opioids). 1 Clinical ... which entails the use of buprenorphine, buprenorphine/naloxone, naltrexone or ... important when developing and improving care management programs, according ... Prime Therapeutics LLC (Prime). ...
Breaking Medicine Technology:Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... , , NEWPORT BEACH, Calif., ... data from a clinical study showing patient-specific cancer vaccines derived ... tolerated and resulted in impressive long-term survival rates in patients ... therapies. , , The study ...
... TARZANA, Calif., July 28 Less than two weeks ... Providence Tarzana Medical Center has applied the body-cooling treatment in ... , , Therapeutic hypothermia treatment, where cardiac ... nationwide to help prevent brain damage caused by a loss ...
Cached Medicine Technology:Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy 2Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy 3Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest 2
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... 2014 Glycodrive , one of ... to help maximize lean, strong muscle growth with a ... of glucose has caught the attention of Shane Michaels, ... behind Glycodrive is to help the body use carbohydrates ... “Carbs are essential in the muscle-building process, and Glycodrive ...
(Date:9/30/2014)... VisitandCare.com reports that revenue ... up more than 79 percent in 2014, marking five ... reported total revenue tripled for its entirety of partnered ... strategy has allowed them to partner with plastic ... comfort and privacy — with state-of-the-art surgical atmospheres aimed ...
(Date:9/30/2014)... A group of Americans is headed to ... that, left unchecked, could create a catastrophic, global pandemic. No, ... Africa. John Rogers, the Executive Director the Eugene Bell Foundation ... a disease most think mankind conquered long ago: tuberculosis. , ... is on the comeback in several countries - what’s especially ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Use of estrogen alone did not increase lung cancer ... online August 13 in The Journal of the ... Health Initiative (WHI) trial, which consisted of several clinical ... previous hysterectomy taking combined estrogen plus progestin therapy had ...
... Reporter , FRIDAY, Aug. 13 (HealthDay News) -- When John D,Amato ... bottle of ibuprofen on the living room floor -- and one ... the pain-reliever container off the coffee table -- where D,Amato had ... pills. "My heart dropped through the floor," he said of ...
... influential medical centers to adopt electronic medical records helps ... Management Insights feature in the current issue of ... for Operations Research and the Management Sciences (INFORMS)., "Social ... Medical Records in U.S. Hospitals" is by Corey M. ...
... over the past 25 years has not translated into ... problems with study design and interpretation, as well as ... 12 in The Journal of the National Cancer ... defines a biomarker as "a characteristic that is objectively ...
... hereditary cancer syndrome may have a role in the regulation of ... the August 15 issue of Genes & Development , a ... called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls ... two major types of liver cells. "We found that ...
... HealthDay Reporter , THURSDAY, Aug. 12 (HealthDay News) ... new study finds that many heart patients aren,t all ... in Australia discovered that patients more often preferred boring ... pressure. "Fifty grams of dark chocolate [roughly one ...
Cached Medicine News:Health News:Estrogen not associated with lung cancer incidence and mortality among postmenopausal women 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 3Health News:Speed electronic medical record adoption via key medical centers, says Management Science 2Health News:The cancer biomarker conundrum: Too many false discoveries 2Health News:Merlin protein found to control liver stem cells, prevent tumor development 2Health News:Many Patients Say 'No' to Chocolate As Medicine 2Health News:Many Patients Say 'No' to Chocolate As Medicine 3
... elbow, wrist, and hand. Appliance holding patient's ... the opposite shoulder. Abduction can be set ... attaches to pillow wedge at 90 angle. ... along length of arm. Humerus and wrist ...
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Shoulder Cryo/Cuff can be ordered with an ... larger chest circumferences.,All Cryo/Cuffs can be ordered ...
... comfortable pre-fabricated orthosis is designed for ... third humeral diaphyseal fractures. The lightweight ... soft tissue compression for optimal control ... range-of-motion of both the shoulder and ...
... to treat or help prevent lower ... hip displasia, foot drop, contractures and pressure ... lining provides a comfortable wicking interface for ... easily rotated and locked into a vertical ...
Medicine Products: